Effect of Eleclazine on Shortening of the QT Interval, Safety, and Tolerability in Adults With Long QT Syndrome Type 3

NCT02300558 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

41

Enrollment

INDUSTRY

Sponsor class

Conditions

Long QT Syndrome Type 3

Interventions

DRUG: Eleclazine
DRUG: Eleclazine placebo

Sponsor

Gilead Sciences